The UCLA Prostate Cancer Index, developed by Mark Litwin, M.D., M.P.H., has become the gold standard worldwide in measuring outcomes and quality of life in prostate cancer survivors.
The UCLA Prostate Cancer Index is now in use in over 200 studies throughout North America and has been translated into Spanish, Dutch, and Japanese for cross-cultural use. Dr. Litwin 's research includes:
He published the first validated instrument to assess disease-targeted health-related quality of life in men treated for prostate cancer and has been an international leader in this area. His research is funded by the National Institute of Diabetes, Digestive and Kidney Diseases, American Cancer Society, California Department of Health Services, and other organizations.